Related Experiment Videos

Plasmid-mediated pristinamycin resistance. PAC IIA: a new enzyme which modifies pristinamycin IIA

Insights

A new enzyme, Pristinamycin acetyltransferase (PAC), inactivates the antibiotic pristinamycin IIA in Staphylococcus aureus. This antibiotic resistance is mediated by a plasmid, highlighting a novel drug resistance mechanism.

Area of Science:

  • Microbiology
  • Molecular Biology
  • Drug Discovery

Background:

  • Staphylococcus aureus is a significant pathogen known for its resistance to various antibiotics.
  • Pristinamycin IIA is a crucial antistaphylococcal antibiotic.
  • Emerging antibiotic resistance mechanisms pose a threat to public health.

Purpose of the Study:

  • To investigate the mechanism by which a wild strain of Staphylococcus aureus inactivates pristinamycin IIA.
  • To identify the genetic basis of this antibiotic inactivation.
  • To characterize the enzyme responsible for the inactivation.

Main Methods:

  • Phenotypic screening of Staphylococcus aureus strains for antibiotic inactivation.
  • Plasmid isolation and characterization.
  • Enzyme assays to determine substrate specificity and activity.
  • Biochemical characterization of the novel enzyme.

Main Results:

  • A wild strain of Staphylococcus aureus was identified that inactivates pristinamycin IIA.
  • The inactivation mechanism was found to be plasmid-mediated.
  • A novel acetyltransferase enzyme, designated PAC (IIA), was identified.
  • PAC (IIA) was shown to O-acetylate pristinamycin IIA, rendering it inactive.

Conclusions:

  • A novel plasmid-mediated mechanism of pristinamycin IIA inactivation by Staphylococcus aureus has been elucidated.
  • The newly discovered enzyme, Pristinamycin acetyltransferase (PAC) (IIA), represents a new class of antibiotic-inactivating enzymes.
  • Understanding this resistance mechanism is crucial for developing strategies to combat antibiotic resistance.

Related Concept Videos